Strados Labs Expands Respiratory Solutions with NuvoAir Acquisition

Strados Labs, a leader in respiratory endpoint intelligence, has announced the acquisition of NuvoAir Clinical Trials from NuvoAir Inc. This strategic move, finalized in March 2026, enhances Strados’ comprehensive suite of solutions, which now includes remote and in-clinic spirometry, FeNO measurement, and electronic clinical outcome assessment (eCOA). With this integration, Strados strengthens its existing offerings in cough monitoring and lung sound analysis, thereby delivering a distinctive end-to-end solution for respiratory trials across all phases, from Phase I to Phase IV.

Comprehensive Endpoint Solutions

The acquisition allows Strados to offer a robust Endpoint Suite that merges advanced technologies for continuous cough monitoring and lung sound analysis through the RESP Biosensor and RESP Watch. Pharmaceutical and biotech sponsors, along with their contract research organization (CRO) partners, can now access a full spectrum of endpoints necessary for their respiratory and pulmonary programs, including those addressing COPD, asthma, and chronic cough. This consolidation means that clients can integrate all required services through a single partner, eliminating the risks associated with handing off data between different providers.

Meeting the Demand for Real-World Measurement

The landscape of respiratory drug development is shifting towards continuous, real-world data collection that transcends the limitations of traditional clinic visits. The Strados Endpoint Suite is meticulously designed to fulfill this need, ensuring high-fidelity monitoring of cough and lung sounds, complete with retained audio for regulatory audits. The suite also incorporates AI-driven event detection alongside hybrid human annotation, allowing for accurate data analysis. Furthermore, live flow curve monitoring during each spirometry maneuver guarantees compliance with ATS 2019 standards at the point of measurement.

A Unique Partnership in Clinical Trials

This acquisition combines two well-established clinical track records into a single endpoint solutions provider. The RESP Biosensor has received two FDA 510(k) clearances and a CE mark, while Strados’ spirometry technology, based on NuvoAir’s Air Next spirometer, has been utilized in over 55 clinical trials worldwide. These studies have addressed a variety of respiratory conditions, including COPD, asthma, IPF, cystic fibrosis, and chronic cough. The regulatory submission data package supporting Strados spirometry enables sponsors to confidently implement remote spirometry in both exploratory and pivotal study designs.

Supporting Continuous Care

Nick Delmonico, CEO and co-founder of Strados Labs, emphasized the necessity of capturing patient data beyond clinic visits. He stated that integrating these capabilities under the Strados Endpoint Suite equips sponsors with a singular solution to gather continuous, structured respiratory data, ensuring data quality and regulatory credibility from the outset.

Chris Skowronek, CEO of NuvoAir, echoed this sentiment, noting that the collaboration with Strados Labs is a natural progression to enhance access and capabilities for organizations in the life sciences sector. This acquisition allows NuvoAir Medical to concentrate on providing exceptional care to patients nationwide.

Commitment to Existing Clients

Strados Labs is committed to ensuring a seamless transition for all existing NuvoAir clinical trial clients. There will be no disruption in ongoing studies, and sponsors and CRO partners with active NuvoAir programs can expect continuity of service, retaining the same operational team while gaining access to the expanded Strados Endpoint Suite as their projects develop.

The Future of Respiratory Measurement

Strados Labs positions itself as the premier provider of respiratory measurement solutions for clinical trials, now enriched by NuvoAir’s proven capabilities. The Strados Endpoint Suite integrates a full range of respiratory measurement tools, including continuous ambulatory cough monitoring, remote and in-clinic spirometry, FeNO, lung sound analysis, and respiratory eCOA. With extensive experience in phases I through IV and a global operational reach, Strados is uniquely equipped to drive drug development forward.

NuvoAir’s Ongoing Mission

NuvoAir continues its commitment to improving care for individuals with respiratory conditions such as COPD, asthma, and sleep apnea. By offering access to both remote and in-person pulmonology specialists and a comprehensive clinical platform that includes the Air Next spirometer, NuvoAir ensures that patients receive the best possible care. This includes a multi-disciplinary care team, longitudinal patient management, and remote pulmonary rehabilitation.

In summary, Strados Labs’ acquisition of NuvoAir Clinical Trials marks a significant advancement in the field of respiratory endpoint solutions. By merging their strengths, both companies are poised to enhance the landscape of respiratory drug development and patient care.

Key Takeaways

• Strados Labs enhances its respiratory solutions with the acquisition of NuvoAir Clinical Trials.

• The Strados Endpoint Suite now offers comprehensive tools for respiratory trials, including spirometry and cough monitoring.

• The integration allows for continuous data collection, improving the understanding of patient outcomes between clinic visits.

• Strados Labs remains committed to supporting existing NuvoAir clients without disrupting ongoing studies.

• NuvoAir will continue to focus on improving care for patients with respiratory conditions through a range of digital health solutions.

Read more → www.pharmabiz.com